129 results
20-F/A
2023 FY
EX-4.87
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
manufacturing controls documents, safety and efficacy study documents as applicable to the Product (“Product Data”) and (ii) other technical … , safety and efficacy data, formulary submissions, pharmaco-economic data, and other such information useful or required in preparing applications
20-F/A
2023 FY
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
Purchasers.
Item 16F.
Change in Registrant’s Certifying Accountant.
Item 16G.
Corporate Governance.
Item 16H.
Mine Safety Disclosure.
PART III
Item 17 … .
The commencement of clinical trials can be delayed for a variety of reasons, including delays in:
demonstrating sufficient safety and efficacy to obtain
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
16 Oct 23
Current report (foreign)
5:23pm
other things, the availability of funding, design and formulation challenges, safety or efficacy, patent issues associated with the product, and FDA … safety and efficacy data for Oxycodone ER that may be obtained from human abuse potential studies for the oral and intranasal routes of administration
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
26 Sep 23
Current report (foreign)
5:29pm
, safety or efficacy, patent issues associated with the product, and FDA and Health Canada review times.
Dexmethylphenidate Hydrochloride … . The Advisory Committees expressed a desire to review the additional safety and efficacy data for Oxycodone ER that may be obtained from human abuse
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
26 Sep 23
Current report (foreign)
5:23pm
, the availability of funding, design and formulation challenges, safety or efficacy, patent issues associated with the product, and FDA and Health Canada … in the product label for the intravenous route of administration. The Advisory Committees expressed a desire to review the additional safety and efficacy
6-K
EX-99.1
0ya8dz0b8
14 Oct 22
Current report (foreign)
4:22pm
6-K
EX-99.1
r57 z10dk
21 Jul 22
Current report (foreign)
5:28pm
20-F/A
pw8 2j68gpr6sf2i6t
6 May 22
Annual report (foreign) (amended)
7:54pm
6-K
EX-99.1
78bwt6eoobev8q8jj
14 Apr 22
Current report (foreign)
4:46pm
6-K
EX-99.3
fx66nfen nrkalipvg7
1 Mar 22
Current report (foreign)
8:04am
6-K
EX-99.1
p5qj4g30u stv9nj
1 Mar 22
Current report (foreign)
8:04am
6-K
EX-99.1
b9jzwim
28 Feb 22
Primary Document
9:56pm
6-K
EX-99.3
rcczt
15 Oct 21
Current report (foreign)
5:22pm
6-K
EX-99.1
i3h1f1 ge
15 Oct 21
Current report (foreign)
5:22pm
6-K
EX-99.1
wklt4qpk221f4df6d0nm
15 Jul 21
Primary Document
4:45pm
6-K
EX-99.3
1wc1yw
15 Jul 21
Primary Document
4:45pm
6-K
EX-99.3
ofllsd je0orfncyb
14 Apr 21
Primary Document
7:50am